Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$264000.0.

  • Spero Therapeutics' Other Working Capital Changes rose 7686.24% to -$264000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year increase of 7926.18%. This contributed to the annual value of -$2.3 million for FY2024, which is 10534.42% down from last year.
  • Latest data reveals that Spero Therapeutics reported Other Working Capital Changes of -$264000.0 as of Q3 2025, which was up 7686.24% from -$319000.0 recorded in Q2 2025.
  • Spero Therapeutics' Other Working Capital Changes' 5-year high stood at $29.0 million during Q4 2022, with a 5-year trough of -$3.5 million in Q3 2022.
  • Over the past 5 years, Spero Therapeutics' median Other Working Capital Changes value was -$363000.0 (recorded in 2025), while the average stood at $1.5 million.
  • The largest annual percentage gain for Spero Therapeutics' Other Working Capital Changes in the last 5 years was 1148235.29% (2022), contrasted with its biggest fall of 59014.37% (2022).
  • Quarter analysis of 5 years shows Spero Therapeutics' Other Working Capital Changes stood at -$255000.0 in 2021, then soared by 11482.35% to $29.0 million in 2022, then tumbled by 110.79% to -$3.1 million in 2023, then soared by 95.4% to -$144000.0 in 2024, then plummeted by 83.33% to -$264000.0 in 2025.
  • Its last three reported values are -$264000.0 in Q3 2025, -$319000.0 for Q2 2025, and -$363000.0 during Q1 2025.